Skip to main content

Table 2 Results for molecular markers analysed

From: Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab

 

Whole group (n = 46)

BRAFV600E

 

Mut

2 (4%)

Wild Type

44 (96%)

PIK3CA exon 20

 

Mut

3 (6%)

Wild Type

43 (94%)

EGFR FISH GCN

 

<2.6

18 (39%)

≥2.6

28 (61%)

HER 3 IHC Score

 

>8

20 (44%)

≤8

26 (56%)

IGF-1 IHC Score

 

≥2

16 (35%)

<2

30 (65%)